BioPharma Clinical Trials
BBM-H803 is Belief BioMed's first gene therapy for the treatment of hemophilia A and is the company's second product which has obtained IND approval from t...
January 04, 2024 | News
Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, ...
January 03, 2024 | News
Under the terms of the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's...
January 03, 2024 | News
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, anno...
January 02, 2024 | News
Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced 510(...
January 02, 2024 | News
The approval is based on the positive results of the pivotal Phase III ReSTORE clinical trial and is supported by STRIVE's Phase II clinical trials and a...
January 01, 2024 | News
The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up ...
January 01, 2024 | News
The proceeds will fund its robust clinical programs and bolster TiumBio's financial position. Data read-outs from a Phase 2 trial of merigolix...
January 01, 2024 | News
Previously, the Company conducted a GSK Shingrix® active-controlled FIH clinical trial of REC610 in the Philippines. The Interim Analysis (IA) res...
December 29, 2023 | News
--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses t...
December 29, 2023 | News
Under the agreement, Innovent will supply sintilimab for the collaborated clinical trial. Xuanzhu Biopharma will conduct a Phase 1b clinical stud...
December 29, 2023 | News
In just one year since the start of the collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific anti...
December 28, 2023 | News
Nectin Therapeutics Ltd., (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology t...
December 27, 2023 | News
On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of anti...
December 27, 2023 | News
Most Read
Bio Jobs
News
Editor Picks